Abstract P1-11-04: Neoadjuvant Z-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor (HER2)- Breast Cancer (BC): Evaluation of the Pharmacokinetic (PK) Run-in for the EVANGELINE Study
Matthew Bidwell Goetz(University of California, Los Angeles), Steven C. Quay(Aptevo Therapeutics (United states)), Pooja Advani(Jacksonville College), Sarah A. Buhrow(Mayo Clinic), Amy C. Degnim(Mayo Clinic in Arizona), Daniel Flora(St. Elizabeth Healthcare), Felipe Batalini(Beth Israel Deaconess Medical Center), Patricia A. Cronin(Mayo Clinic in Arizona), Stephanie L. Safgren(Mayo Clinic), Joel M. Reid(Children's Hospital of Philadelphia), Tufia C. Haddad(Mayo Clinic), Judy C. Boughey(Mayo Clinic in Arizona), John R. Hawse(Mayo Clinic in Arizona), Swaathi Jayaraman(Johns Hopkins University), Sarah Premji, Katie N. Hunt(Mayo Clinic), Nusayba A. Bagegni(Washington University in St. Louis), Amye J. Tevaarwerk, Lida A. Mina(Mayo Clinic in Arizona), Mara A. Piltin(Mayo Clinic), Vera J. Suman(Mayo Clinic in Arizona), James N. Ingle(Mayo Clinic), Jason Jones, Karthik V. Giridhar(WinnMed), Harjinder Singh, Roberto Leon Ferre(Mayo Clinic in Arizona), Arezoo Mirad, Matthew J. Schellenberg(Mayo Clinic)
Cited by 0
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
|Clinical Cancer Research|2013|744